Detalhe da pesquisa
1.
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
N Engl J Med
; 387(2): 132-147, 2022 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35660812
2.
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.
Blood
; 141(7): 756-765, 2023 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36327160
3.
Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice.
Haematologica
; 108(8): 2192-2204, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36546453
4.
Trial designs and endpoints for immune therapies in multiple myeloma.
Am J Hematol
; 98 Suppl 2: S35-S45, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36200130
5.
Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma.
Future Oncol
; 19(18): 1235-1247, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37403937
6.
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Lancet
; 398(10297): 314-324, 2021 07 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34175021
7.
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
N Engl J Med
; 380(18): 1726-1737, 2019 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31042825
8.
Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
Cancer
; 127(11): 1816-1826, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33735504
9.
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States.
Cancer
; 127(1): 82-92, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966625
10.
Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry.
Br J Haematol
; 193(1): 93-100, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33118614
11.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Lancet
; 396(10262): 1563-1573, 2020 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33189178
12.
Case 29-2023: A 34-Year-Old Woman with Abdominal Distention and Acute Kidney Injury.
N Engl J Med
; 389(12): 1133-1143, 2023 Sep 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37733312
13.
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Am J Hematol
; 96(9): 1120-1130, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34062004
14.
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Am J Hematol
; 96(6): 708-718, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33755235
15.
Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis.
Cancer
; 126(19): 4332-4340, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32706404
16.
Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myeloma.
Future Oncol
; 16(19): 1331-1350, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32511022
17.
Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry.
Br J Haematol
; 187(5): 602-614, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31382320
18.
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
Cancer
; 124(22): 4342-4349, 2018 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30395359
19.
Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.
Br J Haematol
; 182(4): 495-503, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29808907
20.
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.
Br J Haematol
; 180(6): 821-830, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29435979